Cornyn Compares Prescription Drug Patent Strategies to Money Laundering

Translate to Spanish or other 102 languages!

James Stansel, Senator John Cornyn, and Michael Carrier
James Stansel, Senator John Cornyn, and Michael Carrier

Mega Doctor News

- Advertisement -

Washington – During a Senate Judiciary Committee hearing on drug pricing, U.S. Senator John Cornyn (R-TX) questioned James Stansel, General Counsel for Pharmaceutical Research and Manufacturers of America, and Michael Carrier, Professor of Law at Rutgers Law School, on pharmaceutical manufacturers’ utilization of the patent system to prevent competition on certain prescription drugs. Excerpts of Sen. Cornyn’s line of questioning are below.

Senator John Cornyn: â€śJust like a financial transaction could be legal in and of itself under certain circumstances, the federal government has defined as money laundering structuring arrangements that are designed to accomplish a certain result… assuming the patent itself was legal, my question is, could they be structured in such a way as to result in an anti-competitive effect?”

James Stansel: â€śWell, I do think that where there’s concern, you know, product hopping has been mentioned, if there’s a specific conduct in the marketplace that a company is engaged in…”

- Advertisement -

Sen. Cornyn: â€śProfessor Carrier, what if we gave the FTC the authority to look at that sort of patent thickets and decide whether there was a noncompetitive effect and provide an equitable remedy?”

Michael Carrier: â€śI think that would make perfect sense and that would deal with the problem here… This is an abuse of the system and giving the FTC power to deal with it will be a great development.”

Senator John Cornyn, a Republican from Texas, is a member of the Senate Finance, Intelligence, and Judiciary Committees.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Cybersecurity Alert as Hackers Exploit Computer and Smartphone Vulnerabilities

Federal cybersecurity authorities are urging computer and smartphone users to keep their devices updated following reports of actively exploited security vulnerabilities affecting Apple products and Google’s Chrome browse

American Cancer Society Updates Prostate Cancer Screening Guideline

The American Cancer Society (ACS) released an updated guideline for prostate cancer screening to help find cancer before it spreads and reduce the risk of dying from the disease.

FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk 

The U.S. Food and Drug Administration today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.” 

Embolism Treatment Developed at University of Michigan receives FDA clearance 

Patients with persistent blood clots require frequent medical interventions just to survive. Yet despite this critical need, there have been few advancements in how these patients are treated. 
- Advertisement -